CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 4 enrolled
Drug / intervention
Amphotericin Bdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02629419
NCT02629419Phase 2Completed
CompareCT.gov

A Phase 2a Efficacy, Safety, Tolerability, and PK Study of Encochleated Amphotericin B (CAMB/MAT2203) in Patients With Mucocutaneous Candidiasis Who Are Refractory or Intolerant to Standard Non-Intravenous Therapies

Matinas BioPharma Nanotechnologies, Inc.·interventional·Posted Dec 14, 2015·Updated Aug 7, 2024

In Brief

A Phase 2 clinical trial evaluating Amphotericin B for Candidiasis, Chronic Mucocutaneous. Completed, enrolled 4 participants across 1 site.

Detailed Summary

This is an open-label, dose-titration trial to study the efficacy, safety, and pharmacokinetics of oral cochleate amphotericin B (CAMB) in the treatment of mucocutaneous candidiasis infections in patients who are refractory or intolerant to standard non intravenous therapies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCandidiasis, Chronic Mucocutaneous
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 14, 2015
Enrollment StartSep 27, 2016
Primary CompletionNov 9, 2021
Study CompletionAug 6, 2022
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 10.5 years ago

Interventions

Amphotericin Bdrug

Oral lipid nanocrystal formulation of amphotericin B